Literature DB >> 3815906

A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis.

B Ljungberg, M Blombäck, H Johnsson, L E Lins.   

Abstract

A low molecular heparin fragment (Fragmin, mol. wt. 4-6000 d), given as a single injection (dose 5000 anti-Xa U), was used as an anticoagulant during hemodialysis in 11 patients. In comparison, our routine heparinization procedure was used; conventional heparin was given as a bolus injection at the start and then as continuous infusion during dialysis to prolong the whole blood activated clotting time (WBACT) 125-175%. Fibrin formation, followed by visual inspection and the measuring of fibrinopeptide A and fibrin monomer concentrations were equally suppressed by the two regimens. WBACT was less prolonged with Fragmin. Anti-Xa activity above 0.39 U/ml was maintained throughout the dialyses with Fragmin. In conclusion a single dose of Fragmin gives sufficient anticoagulation for hemodialysis lasting up to 4 hours.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3815906

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  5 in total

1.  Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin).

Authors:  H Swars; G Hafner; L S Weilemann; W Ehrenthal; H Schinzel; W Prellwitz; J Meyer
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

Review 2.  Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease.

Authors:  C J Dunn; B Jarvis
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

Review 3.  Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders.

Authors:  C J Dunn; E M Sorkin
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

Review 4.  Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins.

Authors:  M Verstraete
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

5.  An Adjustable Dalteparin Sodium Dose Regimen for the Prevention of Clotting in the Extracorporeal Circuit in Hemodialysis: A Clinical Trial of Safety and Efficacy (the PARROT Study).

Authors:  Steven Soroka; Mohsen Agharazii; Sandra Donnelly; Louise Roy; Norman Muirhead; Serge Cournoyer; Martin MacKinnon; Neesh Pannu; Brendan Barrett; François Madore; Karthik Tennankore; Jo-Anne Wilson; Fiona Hilton; Nancy Sherman; Kevin Wolter; John Orazem; Guillaume Feugère
Journal:  Can J Kidney Health Dis       Date:  2018-11-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.